Register today for Cerus' Lunch Symposium


EAST 2024
Wednesday, January 10, 2024 @ 12:00 - 1:15 pm EST
Signia by Hilton Orlando Bonnet Creek -- Orlando, Florida
Floridian Ballroom, Salon K (Lobby Level)
Lunch Provided

Fibrinogen Supplementation in Hemorrhagic Shock: Role of INTERCEPT® Fibrinogen Complex

Availability of fibrinogen sources (such as cryoprecipitated Antihemophilic Factor, or cryo AHF) can be challenging given their long wait times and short shelf life. Timely administration of fibrinogen and other key clotting factors is essential to controlling hemorrhage associated with fibrinogen deficiency. 

During this workshop, Dr. Jonathan Meizoso, Assistant Professor of Surgery at University of Miami / Ryder Trauma Center, will describe the importance of fibrinogen supplementation during hemorrhagic shock resuscitation, the University of Miami’s early experience with INTERCEPT® Fibrinogen Complex (IFC) and how IFC improves blood availability for patients in need.

Please complete the following information to register for Cerus' Symposium.

This industry-supported activity will be held in conjunction with the EAST Annual Scientific Assembly. It is not part of the official scientific program of EAST.  This course is produced and sponsored by CERUS Corporation and is not approved for CME credit.

*INTERCEPT Fibrinogen Complex is available for immediate use for up to 5 days when stored thawed; when stored frozen, requires thawing prior to use.
†Bleeding associated with fibrinogen deficiency.
‡Broad spectrum transfusion transmitted infection risk reduction.

INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex:

INDICATIONS FOR USE
• Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. 
• Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available. 
• Second-line therapy for von Willebrand disease (vWD). 
• Control of uremic bleeding after other treatment modalities have failed.
Limitations of Use: Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used for replacement of factor VIII. 

CONTRAINDICATIONS
Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.  Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS AND PRECAUTIONS
Only the INTERCEPT Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex.  For management of patients with vWD or factor XIII deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used if recombinant or specific virally-inactivated factor preparations are available. In emergent situations, if recombinant or specific virally-inactivated factor preparations are not available, Pathogen Reduced Cryoprecipitated Fibrinogen Complex may be administered.

Rx only. There is no pathogen inactivation process that has been shown to eliminate all pathogens. ©2023 Cerus Corporation. Cerus, INTERCEPT and the Cerus logo are registered trademarks of Cerus Corporation. | Privacy policy